SALT LAKE CITY, UT, March 19, 2013 /PRNewswire/ - ABL Medical, LLC has officially launched their new SilvrSTAT® Antibacterial Wound Dressing Gel into the United States market. SilvrSTAT® is the first of a new class of medical products based on the company's patented nano-molecular silver technology.
ABL Medical's new SilvrSTAT® is cleared as a 510(k) medical device for the use in the management of 1st and 2nd degree burns, wounds such as stasis ulcers, pressure ulcers, diabetic ulcers, lacerations, abrasions, skin tears, surgical incision sites, device insertion site wounds, graft sites and donor sites.
SilvrSTAT® has been shown in laboratory tests to inhibit the growth of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant strains, including MRSA and VRE, as well as fungi such as Candida albicans.
SilvrSTAT®'s unique technology results in a 32ppm antibacterial wound dressing gel which provides quick and continuous antibacterial activity allowing for efficient wound management. It has no known or expected adverse events due to the low 32ppm silver concentration. Visualization of the wound is possible through the transparent gel. There is no sulfa component or alcohol, and SilvrSTAT® is non-flammable.
"ABL Medical's launch of SilvrSTAT® marks the beginning of a new era for wound dressing gels", said Bob Holladay, CEO of ABL Medical. "Our new multivalent, catalytic, nano-molecular silver technology provides rapid antibacterial activity at extremely low concentrations. In head to head studies, SilvrSTAT® has demonstrated significantly superior bacteria kill times versus other currently available silver products approved for use in wound management. As a result, SilvrSTAT® provides a significant advance in the promotion of a pathogen-free healing environment with no known or expected adverse events," added Holladay.
SilvrSTAT® is currently stocked by major U.S. wholesalers including McKesson, Cardinal, and Owens and Minor and is covered by numerous pharmacy benefit management companies. For more information on SilvrSTAT®, go to www.SilvrSTAT®.com or call the company at 801-763-8000.
About ABL Medical, LLC
ABL Medical, LLC (www.ablmedical.com) was established in 2011 to introduce the company's patented, multivalent, catalytic, nano-molecular silver technology in the biomedical industry. SilvrSTAT®, the first of numerous products expected to be launched by ABL Medical, LLC, has undergone extensive testing by a variety of respected laboratories and researchers. ABL Medical's silver has consistently demonstrated the ability, without any known toxic side effects, to inhibit a wide range of bacteria, viruses, yeast, and molds.
SOURCE ABL Medical, LLC